# Sunshine Guojian Pharmaceutical trials: 59

ClinicalTrials.gov lists 59 trials with Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. as lead sponsor, 16 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.: 59 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/sunshine-guojian-pharmaceutical-shanghai-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 59
- Recruiting or not yet: 16
- Read on: November 19, 2026

## Trials

The 25 newest of 59, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 28, 2026 | NCT07900867 | This Study Will Evaluate the Effect and Safety of 626 in Patients With CLE | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 | Not yet recruiting | Cutaneous Lupus Erythematosus (CLE) | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900867) |
| August 17, 2026 | NCT07767253 | Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 | Recruiting | Dermatitis, Atopic | 246 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07767253) |
| July 16, 2026 | NCT07708181 | A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 | Not yet recruiting | Gout Arthritis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708181) |
| July 9, 2026 | NCT07693738 | A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 | Recruiting | AD | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07693738) |
| April 2, 2026 | NCT07507513 | The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 | Recruiting | Ulcerative Colitis (UC) | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07507513) |
| January 16, 2026 | NCT07349329 | A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 | Not yet recruiting | Axial Spondyloarthritis, Non-Radiographic | 380 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07349329) |
| December 3, 2025 | NCT07261644 | A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 | Recruiting | Ankylosing Spondylitis | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07261644) |
| September 22, 2025 | NCT07185269 | The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1/2 | Recruiting | Systemic Lupus Erythematosus (SLE) | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07185269) |
| July 15, 2025 | NCT07065136 | Evaluation of 627 in Healthy Adult Subjects | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Subjects (HS) | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07065136) |
| June 27, 2025 | NCT07042126 | Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 | Recruiting | Dermatitis, Atopic | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07042126) |
| June 27, 2025 | NCT07042113 | A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 | Not yet recruiting | Atopic Dermatitis | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07042113) |
| June 26, 2025 | NCT07039669 | Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 | Recruiting | Pulmonary Disease, Chronic Obstructive (COPD) | 594 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07039669) |
| November 8, 2024 | NCT06680947 | A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 | Active not recruiting | Asthma | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06680947) |
| November 5, 2024 | NCT06674525 | Evaluation of 626 in Healthy Adult Subjects | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 | Completed | Healthy Subjects (HS) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06674525) |
| October 15, 2024 | NCT06639295 | A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 | Active not recruiting | Sinusitis, Nasal Polyps | 243 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06639295) |
| August 15, 2024 | NCT06554847 | Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 | Completed | Dermatitis, Atopic, Eczema, Atopic | 417 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06554847) |
| August 1, 2024 | NCT06533605 | Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 | Unknown | Advanced Solid Tumors Patients | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06533605) |
| July 26, 2024 | NCT06522828 | A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 | Unknown | Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06522828) |
| July 10, 2024 | NCT06493760 | A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 | Recruiting | Metastatic Colorectal Cancer | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06493760) |
| May 14, 2024 | NCT06412471 | A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 | Unknown | First-line Advanced NSCLC Patients | 235 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06412471) |
| April 30, 2024 | NCT06390774 | A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 | Recruiting | Locally Advanced, Recurrent or Metastatic Malignancies | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06390774) |
| April 12, 2024 | NCT06361927 | A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 | Unknown | NSCLC | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06361927) |
| March 22, 2024 | NCT06324812 | Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1/2 | Completed | Dermatitis, Atopic | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06324812) |
| March 21, 2024 | NCT06323213 | Efficacy and Safety Study of 610 in Patients With Severe Asthma | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 | Recruiting | Asthma | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06323213) |
| March 8, 2024 | NCT06299982 | An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 | Unknown | Plaque Psoriasis Patients | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06299982) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 18 |
| Phase 1/2 | 4 |
| Phase 2 | 22 |
| Phase 3 | 14 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 28 |
| Completed | 13 |
| Recruiting | 11 |
| Not yet recruiting | 5 |
| Active not recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Dermatitis, Atopic | 8 |
| Asthma | 4 |
| Retinal Vein Occlusion | 3 |
| Spondylitis, Ankylosing | 3 |
| Colorectal Neoplasms | 3 |
| Arthritis, Gouty | 3 |
| Sinusitis | 2 |
| Nasal Polyps | 2 |
| Pulmonary Eosinophilia | 2 |
| Non-Radiographic Axial Spondyloarthritis | 2 |
| Sarcoma | 2 |
| Psoriasis | 2 |
| Pulmonary Disease, Chronic Obstructive | 2 |
| Polyps | 1 |
| Endometrial Neoplasms | 1 |
| Axial Spondyloarthritis | 1 |
| Lupus Erythematosus, Systemic | 1 |
| Lung Diseases | 1 |
| Lupus Erythematosus, Cutaneous | 1 |
| Recurrence | 1 |
| Neoplasms | 1 |
| Arthritis, Juvenile | 1 |
| Macular Edema | 1 |
| Colitis, Ulcerative | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Stock brokers in the United States](https://specstream.ai/data/businesses/stock-brokers/united-states)
- [Lighting fixture manufacturers in the United States](https://specstream.ai/data/businesses/lighting-fixture-manufacturers/united-states)
- [Criminal defense law firms in the United States](https://specstream.ai/data/businesses/criminal-defense-law-firms/united-states)
- [Vietnamese restaurants in the United States](https://specstream.ai/data/businesses/vietnamese-restaurants/united-states)
- [Ophthalmology practices in the United States](https://specstream.ai/data/businesses/ophthalmology-practices/united-states)
